Protein aggregation has been recognized as one of the major challenges in the
development and commercialization of successful protein-based drug products because of …

The benefits of polyclonal antibodies as tools for assay-specific target discovery and
detection are numerous. As the future of basic research, diagnostics and biomarker …

Biopharmaceuticals are one of the fastest growing areas within the pharmaceutical industry.
As protein drugs require parenteral administration, they are commonly formulated as …

Viscosity of protein solution is one of the most troublesome issues for the high-concentration
formulation of protein drugs. In this review, we summarize the practical methods that …

Protein misfolding is a detrimental effect which can lead to the inactivation of enzymes,
aggregation, and the formation of insoluble protein fibrils called Amyloids. Consequently, it …

Monoclonal antibodies display complicated solution properties in highly concentrated (> 100
mg/mL) formulations, such as high viscosity, high aggregation propensity, and low stability …

Ovarian cancer is the second most leading gynecological cancer after endometrial cancer in
women. Chemotherapy and cyto-reductive surgery are currently the mainstays for treatment …

High protein concentration formulations are required for low-volume administration of
therapeutic antibodies targeted for subcutaneous, self-administration by patients. Ultra-high …

Monoclonal antibodies constitute one of the largest groups of drugs to treat cancers and
immune disorders, and are guiding the design of vaccines against infectious diseases …

Successful development of marketable freeze-dried protein formulations requires adequate
stabilization of the active biopharmaceutical ingredient. The choice of a stabilizer must …